{"id":571899,"date":"2025-12-23T00:00:00","date_gmt":"2025-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0010-2025-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-geographic-focus-china-non-hodgkins\/"},"modified":"2026-05-13T11:15:20","modified_gmt":"2026-05-13T11:15:20","slug":"concon0010-2025-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-geographic-focus-china-non-hodgkins","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0010-2025-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-geographic-focus-china-non-hodgkins\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia &#8211; Geographic Focus: China &#8211; Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia &#8211; China In-Depth (China)"},"content":{"rendered":"<p>The <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced targeted treatments, such as Roche\u2019s Polivy and Gazyva, BeiGene\u2019s Brukinsa, InnoCare\u2019s Hibruka, <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies, and bispecific antibodies. Despite these novel therapies, rituximab (Roche\u2019s MabThera, biosimilars) will maintain its dominance owing to its established position in the treatment paradigm. Growth is further fueled by rising diagnosed incidence, likely due to an aging population and advancements in personalized medicine, which arise from a deeper understanding of the genetic changes underlying <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>. This report evaluates how clinical and nonclinical factors\u2014price dynamics, inclusion in China\u2019s National Reimbursement Drug List (<abbr title=\"National Reimbursement Drug List\">NRDL<\/abbr>), and the entry of generics or biosimilars\u2014will influence the launch and uptake of new and existing therapies. Understanding the impact of these intersecting factors will be crucial for the success of key players in this highly competitive market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the size of clinically and commercially relevant drug-treatable <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> population, and how is the disease currently managed?<\/li>\n<li>What are the key unmet needs in the management of <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>?<\/li>\n<li>Which are the key future players and what factors are driving growth in the <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> market?<\/li>\n<li>What are interviewed experts\u2019 insights into new and existing therapies?<\/li>\n<li>What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy in China.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.<\/li>\n<\/ul>\n<p><strong>Release date:<\/strong><\/p>\n<p>December 2025<\/p>\n<p><strong>Geography:<\/strong><\/p>\n<p>China<\/p>\n<p><strong>Primary research:<\/strong><\/p>\n<p>Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists in China<\/p>\n<p><strong>Epidemiology:<\/strong><\/p>\n<p>Diagnosed incidence of non-Hodgkin\u2019s lymphoma in urban versus rural China, clinically relevant and market-relevant drug-treatable populations.<\/p>\n<p><strong>Forecast:<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient share of key non-Hodgkin\u2019s lymphoma therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p><strong>Drug treatments<\/strong><\/p>\n<p>Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Custom drug modeler<\/strong><\/p>\n<p>Integrated tool to input customized forecast assumptions (e.g., launch date, price)<\/p>\n","protected":false},"template":"","class_list":["post-571899","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571899\/revisions"}],"predecessor-version":[{"id":572131,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571899\/revisions\/572131"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=571899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}